Dr Reddy's Laboratories Q1 2025 GAAP EPS ₹83.46 Beats ₹76.83 Estimate, Sales ₹76.727B Beat ₹72.830B Estimate
Portfolio Pulse from Benzinga Newsdesk
Dr Reddy's Laboratories (NYSE:RDY) reported Q1 2025 earnings per share (EPS) of ₹83.46, beating the analyst estimate of ₹76.83. Sales were ₹76.727 billion, surpassing the estimate of ₹72.830 billion. Despite a slight decrease in EPS from last year, sales increased by 13.87%.
July 29, 2024 | 5:22 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Dr Reddy's Laboratories reported better-than-expected Q1 2025 earnings and sales. EPS was ₹83.46, beating the estimate of ₹76.83, and sales were ₹76.727 billion, exceeding the estimate of ₹72.830 billion. Despite a slight year-over-year decrease in EPS, sales showed significant growth.
The company's earnings and sales both exceeded analyst expectations, which is generally a positive indicator for the stock price. The significant increase in sales also suggests strong business performance.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100